Calcium channel blockers exert their effects by blocking the L-type voltage-gated calcium channels in the heart, vascular smooth muscle, and other tissues such as the pancreas. These L-type channels are responsible for the inward flow of calcium ions, which is critical for muscle contraction, including both cardiac and smooth muscle. By inhibiting calcium influx, CCBs reduce muscle contraction and promote relaxation, resulting in vasodilation and reduced cardiac workload.
The two main types of CCBs—dihydropyridines and non-dihydropyridines—differ in their physiological effects due to their site of action. Dihydropyridines, such as amlodipine and nifedipine, primarily act on vascular smooth muscle, causing potent vasodilation and leading to a decrease in systemic vascular resistance. This makes them highly effective for lowering blood pressure in hypertensive patients. At therapeutic doses, dihydropyridines have minimal effects on the myocardium (heart muscle), allowing them to lower blood pressure without significantly affecting heart rate or cardiac contractility. These properties make dihydropyridines useful in treating hypertension, coronary artery disease, and conditions like post-intracranial hemorrhage vasospasm.
In contrast, non-dihydropyridines (e.g., verapamil and diltiazem) have a dual effect. They act not only on vascular smooth muscle but also directly on the myocardium and the electrical conduction system of the heart. Specifically, they inhibit calcium ion influx at the SA node (sinoatrial) and AV node (atrioventricular), slowing down heart rate and decreasing cardiac contractility. This mechanism allows non-dihydropyridines to be effective in managing supraventricular tachycardias, such as PSVT, and in controlling the ventricular rate in atrial fibrillation/flutter. Moreover, their ability to reduce myocardial oxygen demand by decreasing heart rate and contractility makes them suitable for treating chronic stable angina and vasospastic angina.
In both types of CCBs, the reduction in calcium entry into cells also results in lower oxygen demand for the heart and increased oxygen supply to the myocardial tissue, making them particularly useful in ischemic conditions. CCBs can reduce the frequency and severity of angina episodes by improving myocardial oxygen balance and decreasing afterload, the resistance the heart must overcome to pump blood. The vasodilatory effects also help in peripheral circulation, which is beneficial in conditions like Raynaud’s phenomenon and pulmonary hypertension.
| Feature | Dihydropyridines | Non-dihydropyridines |
|---|---|---|
| Examples | Amlodipine, nifedipine, felodipine, nicardipine | Verapamil, diltiazem |
| Primary site of action | Vascular smooth muscle; potent vasodilation and reduced systemic vascular resistance | Vascular smooth muscle plus myocardium and SA/AV nodal conduction |
| Heart rate and contractility | Minimal myocardial effect at therapeutic doses | Slows SA and AV nodal conduction, reducing heart rate and contractility |
| Main indications | Hypertension (including isolated systolic hypertension in older adults), coronary artery disease, chronic stable angina | PSVT conversion and prophylaxis, rate control in atrial fibrillation/flutter, chronic stable angina, vasospastic (Prinzmetal) angina |
| Common adverse effects | Lightheadedness, flushing, headache, peripheral edema from fluid redistribution into the interstitium | Constipation, orthostatic hypotension, elevated liver enzymes, dizziness, fatigue |
| Serious adverse effects | Acute myocardial infarction, exacerbated angina, acute hypotension, syncope, erythema multiforme, hepatitis | Bradycardia, reflex tachycardia, AV block, arrhythmias, severe hypotension, heart failure exacerbation, Stevens-Johnson syndrome, paralytic ileus, hepatotoxicity |
| Contraindications | Class-wide: hypersensitivity, severe hypotension, acute myocardial infarction, pulmonary congestion; caution in renal or hepatic impairment | Class-wide contraindications plus HFrEF, second- or third-degree AV block without a pacemaker, systolic blood pressure below 90 mmHg, sick sinus syndrome |
